Gastrointestinal Hospital, Sun Yat-sen University | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder	Recruiting	Phase 2	2026-09-09		NCT07809893
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder	Active, not recruiting	Phase 3	2026-05-22		NCT04230187
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder	Recruiting	Phase 2	2025-07-23		NCT05571644
Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer	Metastatic Colorectal Cancer，NED	Recruiting	Phase 2	2023-12-12		NCT05360277
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm	Recruiting	Not applicable	2023-09-21		NCT06043999